On the basis of these findings, we propose to conduct a double-blinded clinical trial using humanized neutralizing anti-CD1d and anti-hVα24Jα18 antibodies at multiple centers to establish a novel therapy for human EoE. This evidence concerns the gene CD1D and eosinophilic esophagitis.